South America Biosimilars Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)
The South America biosimilars market is expected to grow from US$ 1,394.55 million in 2022 to US$ 8,449.92 million by 2028. It is estimated to grow at a CAGR of 35.0% from 2022 to 2028.
Collaborations for Biosimilars and Clinical Trials is Driving South America Biosimilars Market
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years. By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding. Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer. There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.
The immense potential of the biosimilars market has led to many recent, high-profile collaborations. Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
South America Biosimilars Market Overview
The Rest of South America countries comprises of Chile, Colombia, Peru, and among others. According to National Library of Medicine (NLM) in 2020, there has been an increasing prevalence of type 2 diabetes in Chile's adult population over time. According to type 1 diabetes index, in 2022, ~36,874 people are living with type 1 diabetes in Chile. Furthermore, the prevalence of gestational diabetes is being observed in Chile and Colombia. The prevalence rates are ranging from 3.18% to 11.2% in Chile, and 0.34% to 2.03% in Colombia. According to an article published in the Lancet Regional Health Americas in 2022, cancer is the leading of death in rest of South and Central America countries. ~1.5 million new cases and 700,000 deaths occur every year with incidence and rates of 186.5 and 86.6 per 100,000. The most common cancers in 2020 were prostate 15%, breast 14%, colorectal 9%, lung 7%, and stomach 5%. Lung cancer remained the leading cause of cancer death which accounted for 12%.
According to Generics and Biosimilars Initiative (GaBi) in 2022, Instituto Nacional de Vigilancia de Medicamentos y Alimentos, (INVIMA), has approved four biosimilars within the product classes of insulin, tumor necrosis factor (TNF) inhibitor, follicle stimulating hormone (FSH) for use in Colombia. Thus, increasing cases of chronic diseases and growing product approval in rest of South and Central America is driving the growth of biosimilar market.
South America Biosimilars Market Revenue and Forecast to 2028 (US$ Million)
South America Biosimilars Market Segmentation
The South America biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.
The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.
Based on country, the South America biosimilars market is segmented into Brazil, Argentina, and the Rest of South America. Brazil dominated the market in 2022.
Amgen Inc; Sanofi SA; Biocon Ltd; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd are the leading companies operating in the South America biosimilars market.
Collaborations for Biosimilars and Clinical Trials is Driving South America Biosimilars Market
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years. By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding. Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer. There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.
The immense potential of the biosimilars market has led to many recent, high-profile collaborations. Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
South America Biosimilars Market Overview
The Rest of South America countries comprises of Chile, Colombia, Peru, and among others. According to National Library of Medicine (NLM) in 2020, there has been an increasing prevalence of type 2 diabetes in Chile's adult population over time. According to type 1 diabetes index, in 2022, ~36,874 people are living with type 1 diabetes in Chile. Furthermore, the prevalence of gestational diabetes is being observed in Chile and Colombia. The prevalence rates are ranging from 3.18% to 11.2% in Chile, and 0.34% to 2.03% in Colombia. According to an article published in the Lancet Regional Health Americas in 2022, cancer is the leading of death in rest of South and Central America countries. ~1.5 million new cases and 700,000 deaths occur every year with incidence and rates of 186.5 and 86.6 per 100,000. The most common cancers in 2020 were prostate 15%, breast 14%, colorectal 9%, lung 7%, and stomach 5%. Lung cancer remained the leading cause of cancer death which accounted for 12%.
According to Generics and Biosimilars Initiative (GaBi) in 2022, Instituto Nacional de Vigilancia de Medicamentos y Alimentos, (INVIMA), has approved four biosimilars within the product classes of insulin, tumor necrosis factor (TNF) inhibitor, follicle stimulating hormone (FSH) for use in Colombia. Thus, increasing cases of chronic diseases and growing product approval in rest of South and Central America is driving the growth of biosimilar market.
South America Biosimilars Market Revenue and Forecast to 2028 (US$ Million)
South America Biosimilars Market Segmentation
The South America biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.
The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.
Based on country, the South America biosimilars market is segmented into Brazil, Argentina, and the Rest of South America. Brazil dominated the market in 2022.
Amgen Inc; Sanofi SA; Biocon Ltd; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd are the leading companies operating in the South America biosimilars market.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South America BiosimilaSrs Market – by Disease Indication
1.3.2 South America Biosimilars Market – by Drug class
1.3.3 South America Biosimilars Market – by Route of Administration
1.3.4 South America Biosimilars Market – by End User
1.3.5 South America Biosimilars Market – by Country
2. SOUTH AMERICA BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SOUTH AMERICA BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 South America PEST Analysis
4.3 Expert’s Opinion
5. SOUTH AMERICA BIOSIMILARS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Cost Effectiveness of Biosimilar Drugs
5.1.3 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trend
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. BIOSIMILARS MARKET – SOUTH AMERICA ANALYSIS
6.1 South America Biosimilars Market Revenue Forecast and Analysis
7. SOUTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY DISEASE INDICATION
7.1 Overview
7.2 South America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.3 Psoriasis:
7.5.3.1 Overview
7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.4 Arthritis:
7.5.4.1 Overview
7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others:
7.5.5.1 Overview
7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Others Disease Indications
7.6.1 Overview
7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8. SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECAST TO 2028 – BY DRUG CLASS
8.1 Overview
8.2 South America Biosimilars Market, by Drug class 2021 & 2028 (%)
8.3 Granulocyte colony-stimulating factors
8.3.1 Overview
8.3.2 Granulocyte colony-stimulating factors Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Insulin
8.4.1 Overview
8.4.2 Insulin Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 TNF Blockers and Monoclonal Antibodies
8.5.1 Overview
8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
9.1 Overview
9.2 South America Biosimilars Market, by Application 2021 & 2028 (%)
9.3 Intravenous
9.3.1 Overview
9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Subcutaneous
9.4.1 Overview
9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. SOUTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY END USER
10.1 Overview
10.2 South America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Homecare
10.5.1 Overview
10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Other
10.6.1 Overview
10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11. SOUTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
11.1 Overview
11.1.1 South America: Biosimilars Market, by Country, 2021 & 2028 (%)
11.1.1.1 Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 Brazil: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.1.3.1 Brazil: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.1.4 Brazil: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.1.5 Brazil: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 Brazil: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 Argentina: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.2.3.1 Argentina: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.2.4 Argentina: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.2.5 Argentina: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.6 Argentina: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 Rest of South America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Rest of South America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 Rest of South America: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.3.3.1 Rest of South America: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.3.4 Rest of South America: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.3.5 Rest of South America: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.6 Rest of South America: Biosimilars Market, by End User, 2019–2028 (US$ Million)
12. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Biosimilars Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Amgen Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Sanofi SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Biocon Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Eli Lilly and Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sandoz AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South America BiosimilaSrs Market – by Disease Indication
1.3.2 South America Biosimilars Market – by Drug class
1.3.3 South America Biosimilars Market – by Route of Administration
1.3.4 South America Biosimilars Market – by End User
1.3.5 South America Biosimilars Market – by Country
2. SOUTH AMERICA BIOSIMILARS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SOUTH AMERICA BIOSIMILARS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 South America PEST Analysis
4.3 Expert’s Opinion
5. SOUTH AMERICA BIOSIMILARS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Cost Effectiveness of Biosimilar Drugs
5.1.3 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trend
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. BIOSIMILARS MARKET – SOUTH AMERICA ANALYSIS
6.1 South America Biosimilars Market Revenue Forecast and Analysis
7. SOUTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY DISEASE INDICATION
7.1 Overview
7.2 South America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.3 Psoriasis:
7.5.3.1 Overview
7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.4 Arthritis:
7.5.4.1 Overview
7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others:
7.5.5.1 Overview
7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Others Disease Indications
7.6.1 Overview
7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8. SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECAST TO 2028 – BY DRUG CLASS
8.1 Overview
8.2 South America Biosimilars Market, by Drug class 2021 & 2028 (%)
8.3 Granulocyte colony-stimulating factors
8.3.1 Overview
8.3.2 Granulocyte colony-stimulating factors Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Insulin
8.4.1 Overview
8.4.2 Insulin Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 TNF Blockers and Monoclonal Antibodies
8.5.1 Overview
8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. SOUTH AMERICA BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION
9.1 Overview
9.2 South America Biosimilars Market, by Application 2021 & 2028 (%)
9.3 Intravenous
9.3.1 Overview
9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Subcutaneous
9.4.1 Overview
9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. SOUTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – BY END USER
10.1 Overview
10.2 South America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Homecare
10.5.1 Overview
10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Other
10.6.1 Overview
10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11. SOUTH AMERICA BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
11.1 Overview
11.1.1 South America: Biosimilars Market, by Country, 2021 & 2028 (%)
11.1.1.1 Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 Brazil: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.1.3.1 Brazil: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.1.4 Brazil: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.1.5 Brazil: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 Brazil: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 Argentina: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.2.3.1 Argentina: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.2.4 Argentina: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.2.5 Argentina: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.6 Argentina: Biosimilars Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 Rest of South America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Rest of South America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 Rest of South America: Biosimilars Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.3.3.1 Rest of South America: Biosimilars Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.3.4 Rest of South America: Biosimilars Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.3.5 Rest of South America: Biosimilars Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.6 Rest of South America: Biosimilars Market, by End User, 2019–2028 (US$ Million)
12. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Biosimilars Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Amgen Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Sanofi SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Biocon Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Eli Lilly and Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sandoz AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Comparison Between Different Drug Developments
Table 2. Brazil Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. Brazil Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 4. Brazil Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 5. Brazil Biosimilars Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 6. Brazil Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Argentina Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 8. Argentina Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 9. Argentina Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 10. Argentina Biosimilars Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 11. Argentina Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. Rest of South America Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. Rest of South America Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 14. Rest of South America Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of South America Biosimilars Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of South America Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 18. Recent Organic Growth Strategies in the Biosimilars Market
Table 19. Glossary of Terms
Table 1. Comparison Between Different Drug Developments
Table 2. Brazil Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. Brazil Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 4. Brazil Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 5. Brazil Biosimilars Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 6. Brazil Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Argentina Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 8. Argentina Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 9. Argentina Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 10. Argentina Biosimilars Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 11. Argentina Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. Rest of South America Biosimilars Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. Rest of South America Biosimilars Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 14. Rest of South America Biosimilars Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of South America Biosimilars Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of South America Biosimilars Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 18. Recent Organic Growth Strategies in the Biosimilars Market
Table 19. Glossary of Terms
LIST OF FIGURES
Figure 1. South America Biosimilars Market Segmentation
Figure 2. South America Biosimilars Market, by Country
Figure 3. South America Biosimilars Market Overview
Figure 4. Cancer Segment Held Largest Share of Type Segment in South America Biosimilars Market
Figure 5. Argentina is Expected to Show Remarkable Growth During Forecast Period
Figure 6. South America: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. South America Biosimilars Market Impact Analysis of Drivers and Restraints
Figure 9. South America Biosimilars Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. South America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
Figure 11. Cancer: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Autoimmune Diseases: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Psoriasis: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Arthritis: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others Disease Indications: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. South America Biosimilars Market, by Drug class 2021 & 2028 (%)
Figure 19. Granulocyte colony-stimulating factors Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Insulin Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. South America Biosimilars Market, by Application 2021 & 2028 (%)
Figure 24. Intravenous: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Subcutaneous: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. South America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Homecare: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Other: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. South America: Biosimilars Market, by Key Country – Revenue (2021) (US$ Million)
Figure 33. South America: Biosimilars Market, by Country, 2021 & 2028 (%)
Figure 34. Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Rest of South America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Growth Strategies in the Biosimilars Market
Figure 1. South America Biosimilars Market Segmentation
Figure 2. South America Biosimilars Market, by Country
Figure 3. South America Biosimilars Market Overview
Figure 4. Cancer Segment Held Largest Share of Type Segment in South America Biosimilars Market
Figure 5. Argentina is Expected to Show Remarkable Growth During Forecast Period
Figure 6. South America: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. South America Biosimilars Market Impact Analysis of Drivers and Restraints
Figure 9. South America Biosimilars Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. South America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
Figure 11. Cancer: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Autoimmune Diseases: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Psoriasis: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Arthritis: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others Disease Indications: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. South America Biosimilars Market, by Drug class 2021 & 2028 (%)
Figure 19. Granulocyte colony-stimulating factors Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Insulin Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others Drug class: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. South America Biosimilars Market, by Application 2021 & 2028 (%)
Figure 24. Intravenous: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Subcutaneous: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. South America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Homecare: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Other: South America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. South America: Biosimilars Market, by Key Country – Revenue (2021) (US$ Million)
Figure 33. South America: Biosimilars Market, by Country, 2021 & 2028 (%)
Figure 34. Brazil: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Argentina: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Rest of South America: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Growth Strategies in the Biosimilars Market
